EyePoint Pharmaceuticals, Inc. (EYPT)

In the past six months, EyePoint Pharmaceuticals raised approximately $150 million through a public offering in October 2025 and launched its Phase 3 DURAVYU program. The company announced Q2 2025 earnings in August 2025, reporting an EPS of -$0.85 and revenue of $5.3 million, missing analyst estimates. In May 2025, the stock tumbled 21% despite positive clinical trial results for DURAVYU in the Phase 2 VERONA trial for DME. The company also reported rapid enrollment progress in its Phase 3 LUGANO trial for DURAVYU in wet AMD in May 2025 and presented 24-week topline results from the Phase 2 VERONA study in DME. In November 2024, EyePoint completed a $161 million follow-on public offering of common stock, and in December 2023, a $230 million follow-on public offering.

Information regarding the specific demand seasonality for EyePoint Pharmaceuticals' products and services is not readily available.

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases. The company's portfolio includes FDA-approved products like YUTIQ for chronic non-infectious uveitis and DEXYCU for postoperative inflammation. Their lead product candidate is DURAVYU, an investigational sustained-delivery treatment for VEGF-mediated retinal diseases, currently in Phase 3 clinical trials for wet AMD, NPDR, and DME. EyePoint also has EYP-2301 in preclinical development for retinal diseases.

EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts, and has a commercial manufacturing site in Northbridge, Massachusetts. While primarily focused on the U.S. market for DURAVYU, EyePoint is exploring partnerships for international markets.

EyePoint Pharmaceuticals is known for its commitment to developing innovative therapies for retinal diseases and aims to be the first to market with a TKI for wet AMD by 2027. Positive developments like the successful End-of-Phase 2 meeting with the FDA for DURAVYU in DME and encouraging results from the Phase 2 VERONA study have bolstered its reputation. However, the company faced challenges due to an FDA warning letter concerning manufacturing shortfalls at its Watertown facility and disappointing results from the Phase 2 PAVIA study for Duravyu in non-proliferative diabetic retinopathy.

EyePoint Pharmaceuticals has significant institutional ownership, with approximately 99.41% of its stock held by institutions including Cormorant Asset Management, LP, Suvretta Capital Management, LLC, and BlackRock, Inc. Insiders hold approximately 4.46% of the stock, with key individual and insider owners including Ew Healthcare Partners LP, Pfizer Inc, and Ronald W. Eastman.